Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949702 · ClinicalTrials.gov registry record · Phase 2
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00949702 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 132 participants.
The verdict
NCT00949702, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive oral Vemurafenib \[RG7204; PLEXXIKON: PLX4032\] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. Target sample size is \<100 patients.
Interventions
- DRUG vemurafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2009-09-30 |
| Est. Completion | 2014-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949702
The ClinicalTrials.gov registry entry for NCT00949702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vemurafenib is the first listed.
NCT00949702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949702 about?
NCT00949702 is a clinical study titled "A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma". This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive oral Vemurafenib \[RG7204; PLEXXIKON: PLX4032\] at a dose of 960 mg b.i.d. continuously until disease progression or withdr...
What is the current status of trial NCT00949702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2009-09-30. Estimated completion is 2014-06-03.
What interventions are being tested in trial NCT00949702?
The interventions under investigation include: vemurafenib (DRUG).
Who is sponsoring clinical trial NCT00949702?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.